Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry

  1. Valeria Ramaglia  Is a corresponding author
  2. Salma Sheikh-Mohamed
  3. Karen Legg
  4. Calvin Park
  5. Olga L Rojas
  6. Stephanie Zandee
  7. Fred Fu
  8. Olga Ornatsky
  9. Eric C Swanson
  10. David Pitt
  11. Alexandre Prat
  12. Trevor D McKee
  13. Jennifer L Gommerman
  1. University of Toronto, Canada
  2. Yale School of Medicine, United States
  3. Université de Montreal, Canada
  4. University Health Network, Canada
  5. Fluidigm Inc, Canada
  6. Université de Montréal, Canada

Abstract

Multiple Sclerosis (MS) is characterized by demyelinated and inflammatory lesions in the brain and spinal cord that are highly variable in terms of cellular content. Here we used imaging mass cytometry (IMC) to enable the simultaneous imaging of 15+ proteins within staged MS lesions. To test the potential for IMC to discriminate between different types of lesions, we selected a case with severe rebound MS disease activity after natalizumab cessation. With post-acquisition analysis pipelines we were able to: (1) Discriminate demyelinating macrophages from the resident microglial pool; (2) Determine which types of lymphocytes reside closest to blood vessels; (3) Identify multiple subsets of T and B cells, and (4) Ascertain dynamics of T cell phenotypes vis-à-vis lesion type and location. We propose that IMC will enable a comprehensive analysis of single-cell phenotypes, their functional states and cell-cell interactions in relation to lesion morphometry and demyelinating activity in MS patients.

Data availability

All data generated and analysed during this study are included in the manuscript and supporting files. Source data file has been provided for Figure 7.

Article and author information

Author details

  1. Valeria Ramaglia

    Department of Immunology, University of Toronto, Toronto, Canada
    For correspondence
    v.ramaglia@utoronto.ca
    Competing interests
    Valeria Ramaglia, received a consulting honorarium from EMD Serono.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9401-5988
  2. Salma Sheikh-Mohamed

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  3. Karen Legg

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  4. Calvin Park

    Department of Neurology, Yale School of Medicine, New Haven, United States
    Competing interests
    No competing interests declared.
  5. Olga L Rojas

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  6. Stephanie Zandee

    Department of Neuroscience, Université de Montreal, Montreal, Canada
    Competing interests
    No competing interests declared.
  7. Fred Fu

    STTARR Innovation center, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  8. Olga Ornatsky

    Fluidigm Inc, Markham, Canada
    Competing interests
    Olga Ornatsky, is an employee of Fluidigm Inc.
  9. Eric C Swanson

    Fluidigm Inc, Markham, Canada
    Competing interests
    Eric C Swanson, is an employee of Fluidigm Inc.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8454-1207
  10. David Pitt

    Department of Neurology, Yale School of Medicine, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6407-9542
  11. Alexandre Prat

    Department of Neurosciences, Faculty of Medicine, Université de Montréal, Montreal, Canada
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6188-0580
  12. Trevor D McKee

    STTARR Innovation center, University Health Network, Toronto, Canada
    Competing interests
    No competing interests declared.
  13. Jennifer L Gommerman

    Department of Immunology, University of Toronto, Toronto, Canada
    Competing interests
    Jennifer L Gommerman, is a consultant for Roche (Canada) and currently holds grants with Novartis, EMD Serono, and Roche.

Funding

National Multiple Sclerosis Society (RR-1602-07777)

  • Valeria Ramaglia

Multiple Sclerosis Society of Canada

  • Jennifer L Gommerman

Multiple Sclerosis Society of Canada

  • Alexandre Prat

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This work included the use of post-mortem brain tissue. Written consent for post-mortem donation of the CNS to research from the MS donor was obtained (ethics committee approval number BH.07.001).Ethical approval for the use of post-mortem brain tissue from the control donor of the Netherlands Brain Bank was obtained (VU Medical Center ethic committee approval Reference number 2009/148)

Copyright

© 2019, Ramaglia et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,850
    views
  • 858
    downloads
  • 60
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Valeria Ramaglia
  2. Salma Sheikh-Mohamed
  3. Karen Legg
  4. Calvin Park
  5. Olga L Rojas
  6. Stephanie Zandee
  7. Fred Fu
  8. Olga Ornatsky
  9. Eric C Swanson
  10. David Pitt
  11. Alexandre Prat
  12. Trevor D McKee
  13. Jennifer L Gommerman
(2019)
Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry
eLife 8:e48051.
https://doi.org/10.7554/eLife.48051

Share this article

https://doi.org/10.7554/eLife.48051

Further reading

    1. Immunology and Inflammation
    Jian Cui, Hua Li ... Congqing Wu
    Short Report

    Systemic blood coagulation accompanies inflammation during severe infections like sepsis and COVID. We previously established a link between coagulopathy and pyroptosis, a vital defense mechanism against infection. During pyroptosis, the formation of gasdermin-D (GSDMD) pores on the plasma membrane leads to the release of tissue factor (TF)-positive microvesicles (MVs) that are procoagulant. Mice lacking GSDMD release fewer of these procoagulant MVs. However, the specific mechanisms coupling the activation of GSDMD to MV release remain unclear. Plasma membrane rupture (PMR) in pyroptosis was recently reported to be actively mediated by the transmembrane protein Ninjurin-1 (NINJ1). Here, we show that NINJ1 promotes procoagulant MV release during pyroptosis. Haploinsufficiency or glycine inhibition of NINJ1 limited the release of procoagulant MVs and inflammatory cytokines, and partially protected against blood coagulation and lethality triggered by bacterial flagellin. Our findings suggest a crucial role for NINJ1-dependent PMR in inflammasome-induced blood coagulation and inflammation.

    1. Immunology and Inflammation
    2. Neuroscience
    Rocio Vicario, Stamatina Fragkogianni ... Frédéric Geissmann
    Research Article

    Somatic genetic heterogeneity resulting from post-zygotic DNA mutations is widespread in human tissues and can cause diseases, however, few studies have investigated its role in neurodegenerative processes such as Alzheimer’s disease (AD). Here, we report the selective enrichment of microglia clones carrying pathogenic variants, that are not present in neuronal, glia/stromal cells, or blood, from patients with AD in comparison to age-matched controls. Notably, microglia-specific AD-associated variants preferentially target the MAPK pathway, including recurrent CBL ring-domain mutations. These variants activate ERK and drive a microglia transcriptional program characterized by a strong neuro-inflammatory response, both in vitro and in patients. Although the natural history of AD-associated microglial clones is difficult to establish in humans, microglial expression of a MAPK pathway activating variant was previously shown to cause neurodegeneration in mice, suggesting that AD-associated neuroinflammatory microglial clones may contribute to the neurodegenerative process in patients.